enVista hydrophobic acrylic intraocular lens
Bausch + Lomb, Inc. · Decision date Sep 3, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-03 for PMA supplement P910056/S063, associated with the enVista hydrophobic acrylic intraocular lens from Bausch & Lomb, Inc. The supplement is filed as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded statement describes the elimination of certain redundant post-coating incoming inspections for coated lens shuttles.
The scope is a manufacturing inspection change affecting a lens shuttle component rather than a new approval of the lens system as a whole. The device category is intraocular lens, specialty Ophthalmic, product code HQL. The source record contains no documents and no document record identifier, so the notice text, inspection rationale and any conditions attached to the decision are not available here and remain unknown.
No clinical, efficacy or patient-selection information is part of this record, and none should be inferred from the decision code alone.
FDA approval order statement
the elimination of certain redundant post-coating incoming inspections for coated lens shuttles
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P910056/S063
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P910056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P910056 · Original PMA
SOFLEX UV-ABSORBING SILICONE POSTERIOR CHAMBER INTRAOCULAR LENS
P910056/S063 received
Application receipt date recorded by FDA.
P910056/S063 · FDA decision
30-Day Notice
P910056/S065 · Related supplement
enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL)
P910056/S064 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
P910056/S066 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
P910056/S067 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
Timeline entries are records held by MedtechLedger for P910056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Jan 17, 1992 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S064 | Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
FINEVISION HP Trifocal IOLsP240038/S003 | Beaver-Visitec International, Inc. | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 50 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P910056/S063
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





